Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Blaze Bioscience Inc.
ClinicalTrials.gov Identifier:
NCT02234297
First received: August 4, 2014
Last updated: April 4, 2016
Last verified: April 2016
  Purpose
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. We hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as operate. This is a safety study to assess the safety of BLZ-100 in patients with gliomas undergoing surgery.

Condition Intervention Phase
Glioma
Drug: BLZ-100
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Glioma Undergoing Surgery

Resource links provided by NLM:


Further study details as provided by Blaze Bioscience Inc.:

Primary Outcome Measures:
  • Number of participants with adverse events [ Time Frame: Seven days after study drug administration ] [ Designated as safety issue: Yes ]
    Safety will be assessed by physical examination and measurement of vital signs and laboratory safety parameters.


Secondary Outcome Measures:
  • Change in concentration of BLZ-100 in the blood [ Time Frame: Prior to dosing and at 1 minute, 5 minutes, 15 mins, 30 mins, 60 mins and 120 mins after end of injection ] [ Designated as safety issue: No ]
    BLZ-100 levels in blood will be analyzed by chemical means and these data will be used to calculate pharmacokinetic parameters.


Other Outcome Measures:
  • Fluoresence signal in excised brain tumor and normal brain cancer [ Time Frame: at least 2 hours post-dose ] [ Designated as safety issue: No ]
    Fluorescence signal in sections of excised tumor and adjacent normal tissue will be measured using an infrared imaging system.


Enrollment: 17
Study Start Date: October 2014
Study Completion Date: March 2016
Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BLZ-100 Drug: BLZ-100
Other Name: Tumor Paint

Detailed Description:

Subjects who provide voluntary written informed consent will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate.

Subjects will be required to arrive at the hospital (or phase 1 unit if applicable) for dosing at least 2 hours before the planned surgical excision. Following dosing, subjects will be monitored for safety and surgical excision will occur at least 2 hours after study product administration.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subjects aged 18- 75 years.
  2. Subjects must have glioma for which surgical resection is clinically indicated. Grade I, II, III and IV glioma patients will be included (for example glioblastoma, astrocytoma, and oligodendroglioma). Histological confirmation not required prior to surgery. Subjects with recurrent disease will be eligible only if the duration between last brain surgery and scheduled new surgery is ≥3 months. The grade of a recurrent tumor will be presumed that of the primary tumor for purposes of group allocation.
  3. Able to provide written informed consent.
  4. If of child-bearing potential, agree to the continued use of effective contraceptive from study entry (Informed consent) through 30 days after BLZ-100 administration.
  5. Available for all study visits and able to comply with all study requirements

Exclusion Criteria:

  1. Evidence of metastatic disease.
  2. Female who is lactating/breastfeeding
  3. Female with a positive pregnancy test or who is planning to become pregnant during the duration of the study.
  4. Karnofsky Performance Status of <60%.
  5. Any of the following laboratory abnormalities at Screening:

    1. Neutrophil count <1.5 x 10^9/L
    2. Platelets <75 x 10^9/L
    3. Hemoglobin <10 g/dL (may be determined following transfusion)
    4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3x upper limit of normal (ULN)
    5. Total bilirubin >1.5x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
    6. International Normalized Ratio (INR) >1.5
    7. Creatinine >1.5x ULN
  6. Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV).
  7. QTc prolongation >450 msec
  8. History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine and/or hospitalization.
  9. Uncontrolled asthma or asthma requiring oral corticosteroids.
  10. Known or suspected sensitivity to MRI contrast agents or excipients in the study drug product.
  11. Known or suspected sensitivity to Indocyanine green (ICG).
  12. Unstable angina, myocardial infarction, known or suspected transient ischemic events or stroke within 24 weeks of start of Screening.
  13. Uncontrolled hypertension.
  14. Receipt of photosensitizing drugs within 30 days of Screening.
  15. Any ongoing medications which might generate fluorescence or according to label, might generate a photochemical reaction. These include haematoporphyrin derivatives and purified fractions; Photofrin®; and the precursors of protoporphyrin IX (5-Aminolevulinic acid) used in Gliolan or Hexvix.
  16. Received an investigational drug or device within 30 days of enrollment.
  17. Prior treatment with BLZ-100.
  18. Any concurrent condition, including psychological and social situations, which, in the opinion of the investigator, would impact adversely on the subject or the interpretation of the study data.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02234297

Locations
United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Australia, Queensland
NEWRO Foundation
Brisbane, Queensland, Australia, Auchenflower
Sponsors and Collaborators
Blaze Bioscience Inc.
Investigators
Principal Investigator: Chirag Patil Cedars-Sinai Medical Center
  More Information

Responsible Party: Blaze Bioscience Inc.
ClinicalTrials.gov Identifier: NCT02234297     History of Changes
Other Study ID Numbers: BB-002 
Study First Received: August 4, 2014
Last Updated: April 4, 2016
Health Authority: United States: Food and Drug Administration
Australia: Therapeutic Goods Administration (TGA)

Keywords provided by Blaze Bioscience Inc.:
Glioma
Tumor Paint
BLZ100

Additional relevant MeSH terms:
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on August 25, 2016